AWP1 Inhibitors
Chemical inhibitors of AWP1 can influence various cellular signaling pathways by directly affecting the activity of this protein. PD98059 and U0126, as selective inhibitors of MEK, inhibit the MAPK/ERK pathway, thus reducing the phosphorylation of ERK and downstream signaling events. This reduction in ERK activity decreases the functional requirement for AWP1's role in stabilizing MAPK pathway phosphatases, such as DUSP6. LY294002 and Wortmannin, both targeting phosphoinositide 3-kinases (PI3K), downregulate AKT signaling pathways. Since AWP1 is implicated in the regulation of the AKT pathway by interacting with components that could affect AKT phosphorylation, these inhibitors lessen the need for AWP1's regulatory functions in this context.
Further affecting AWP1's interaction with signaling molecules, SP600125 inhibits the c-Jun N-terminal kinase (JNK), which is involved in stress-induced apoptosis pathways. This inhibition can reduce the necessity for AWP1's stabilizing interactions with apoptotic regulatory proteins. Similarly, SB203580, a specific inhibitor of p38 MAP kinase, decreases upstream activity in the MAPK pathway, which in turn may lead to a decreased demand for AWP1's regulatory actions. Rapamycin's inhibition of mTOR, a kinase central to cell growth and proliferation, also diminishes the cellular reliance on AWP1's negative regulatory functions within this pathway. PP2, by selectively inhibiting Src family tyrosine kinases, affects various signaling pathways including those related to cell survival, and consequently, the requirement for AWP1's function in these pathways is reduced. Y-27632's inhibition of ROCK, which plays a role in cytoskeletal organization, can affect actin filament formation and potentially reduce the need for AWP1's interaction with cytoskeletal regulatory proteins. Lastly, BAY 11-7082, by inhibiting NF-κB activation, and PD173074, an inhibitor of FGFR tyrosine kinase, both decrease downstream signals that would otherwise necessitate AWP1's regulatory role in these signaling pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a part of the MAPK/ERK pathway. Since AWP1 functions in the negative regulation of this pathway by deubiquitinating and stabilizing phosphatases such as DUSP6, inhibition of MEK by PD98059 would attenuate the need for AWP1's regulatory function, effectively reducing its role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, this compound would downregulate AKT signaling, a pathway in which AWP1 has been implicated. The inhibition of AKT phosphorylation and subsequent signaling cascades would diminish the functional relevance of AWP1's regulatory actions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress-induced apoptosis pathways. AWP1 is known to interact with components in apoptotic pathways, and the inhibition of JNK by SP600125 could reduce the necessity for AWP1's stabilizing interactions with apoptotic regulatory proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. AWP1's role in negative regulation of MAPK signaling suggests that inhibiting upstream kinases like p38 would lead to a decreased functional demand for AWP1, which works on deubiquitinating and stabilizing the MAPK phosphatases. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream activators of ERK1/2 in the MAPK pathway. As AWP1 regulates the MAPK pathway by stabilizing specific phosphatases, the inhibition of MEK1/2 by U0126 reduces the phosphorylation of ERK, thus indirectly reducing the functional requirement for AWP1's stabilizing activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. With PI3K inhibited, downstream signaling including AKT is reduced. Since AWP1 has been associated with the AKT signaling pathway, the inhibition of PI3K by Wortmannin would suppress the signaling that necessitates AWP1's regulatory function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), an important kinase in cell growth and proliferation pathways. AWP1 is involved in the negative regulation of these pathways, and the inhibition of mTOR by Rapamycin would decrease cellular reliance on AWP1's regulatory functions. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 would affect various signaling pathways including those related to cell survival where AWP1 might play a role. The inhibition of Src kinases would reduce the signaling complexity and need for AWP1's function in these pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 selectively inhibits ROCK (Rho-associated protein kinase), which is involved in cytoskeletal organization. AWP1 is known to interact with components affecting the cytoskeleton. The inhibition of ROCK would affect actin filament formation and potentially reduce the need for AWP1's interaction with cytoskeletal regulatory proteins. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinase. FGFR signaling is implicated in various cellular processes, including those that AWP1 may influence. Inhibition of FGFR by PD173074 would decrease downstream signals that necessitate the regulatory role of AWP1. | ||||||